Digital Locations (DLOC) 10-K 30 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 27, 2015	Jun. 30, 2014
Document And Entity Information
Entity Registrant Name	Carbon Sciences, Inc.,
Entity Central Index Key	1407878
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$372,451
Entity Common Stock, Shares Outstanding		265,976,925
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2014
Entity Incorporation, Date of Incorporation	25-Aug-06

BALANCE_SHEETS

BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
CURRENT ASSETS:
Cash	$15,447	$11,382
Prepaid expenses	70,593	3,758
Total current assets	86,040	15,140
PROPERTY AND EQUIPMENT, NET	547	1,182
OTHER ASSETS - Patents		1,784
Total assets	86,587	18,106
CURRENT LIABILITIES:
Accounts payable	160,270	217,418
Accrued expenses and other current liabilities	5,223	11,137
Accrued interest, notes payable	141,434	64,340
Derivative liability	9,476,605	2,811,962
Convertible notes payable, net of beneficial conversion feature of $0 and $8,849, respectively	166,500	157,651
Convertible notes payable, net of discount of $191,265 and $226,445, respectively	654,199	492,904
Total current liabilities	10,604,231	3,755,412
LONG-TERM LIABILITIES
Convertible notes payable, net of discount of $253,883	61,117
Convertible notes payable	25,000	25,000
Total long-term liabilities	86,117	25,000
Total liabilities	10,690,348	25,000
STOCKHOLDERS' DEFICIT:
Preferred stock, $0.001 par value; 20,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.001 par value; 1,000,000,000 shares authorized, 241,186,179 and 72,134,930 shares issued and outstanding	241,186	72,135
Additional paid-in capital	11,309,228	10,614,891
Accumulated deficit	-22,154,175	-14,449,332
Total stockholders' deficit	-10,603,761	-3,762,306
Total liabilities and stockholders' deficit	$86,587	$18,106

BALANCE_SHEETS_Parenthetical

BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred Stock, par or stated value	$0.00	$0.00
Preferred Stock, shares authorized	20,000,000	20,000,000
Preferred Stock, shares issued
Preferred Stock, shares outstanding
Common Stock, par or stated value	$0.00	$0.00
Common Stock, shares authorized	1,000,000,000	1,000,000,000
Common Stock, shares issued	241,186,179	72,134,930
Common Stock, shares outstanding	241,186,179	72,134,930
Convertible promissory notes, beneficial conversion feature	$0	$8,849
Convertible Notes, Current
Convertible promissory notes discount	191,265	226,445
Convertible Notes, Non-Current
Convertible promissory notes discount	$253,883

STATEMENTS_OF_OPERATIONS

STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Statement
REVENUE
OPERATING EXPENSES:
General and administrative	411,126	470,363
Research and development	193,865	439
Depreciation and amortization	635	2,354
Total operating expenses	605,626	473,156
LOSS FROM OPERATIONS	-605,626	-473,156
OTHER INCOME (EXPENSE):
Rental income	13,500	14,250
Impairment of intangible assets	-1,784	0
Gain (loss) on settlement of debt	18,369	-25,195
Gain on forgiveness of debt	0	20,000
Loss on change in derivative liability	-6,529,219	-2,267,693
Interest expense	-600,083	-765,708
Total other income (expense)	-7,099,217	-3,024,346
LOSS BEFORE INCOME TAXES	-7,704,843	-3,497,502
PROVISION FOR INCOME TAXES
NET LOSS	($7,704,843)	($3,497,502)
NET LOSS PER SHARE, BASIC AND DILUTED	($0.05)	($0.13)
WEIGHTED AVERAGE SHARES OUTSTANDING, BASIC AND DILUTED	158,606,001	27,969,047

STATEMENTS_OF_STOCKHOLDERS_DEF

STATEMENTS OF STOCKHOLDERS' DEFICIT (USD $)		Preferred Stock	Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total
Stockholders' Equity, beginning of period, Value at Dec. 31, 2012			$11,577		$9,814,228	($10,951,830)	($1,126,025)
Stockholders' Equity, beginning of period, Shares at Dec. 31, 2012			11,576,680
Contribution of note payable to capital					28,621		28,621
Contribution of accrued interest to capital					7,175		7,175
Beneficial conversion factor for convertible notes payable					123,380		123,380
Issuance of common stock pursuant to price protection agreement, Value			593		-593
Issuance of common stock pursuant to price protection agreement, Shares			592,780
Issuance of common stock for conversion of notes payable, Value			59,965	[1]	540,325		600,290
Issuance of common stock for conversion of notes payable, Shares	[1]		59,965,470
Stock compensation cost					101,755		101,755
Net loss						-3,497,502	-3,497,502
Stockholders' Equity, end of period, Value at Dec. 31, 2013			72,135		10,614,891	-14,449,332	-3,762,306
Stockholders' Equity, end of period, Shares at Dec. 31, 2013			72,134,930
Issuance of common stock for conversion of notes payable, Value			163,051	[2]	613,889		776,940
Issuance of common stock for conversion of notes payable, Shares	[2]		163,051,249
Issuance of common stock for accrued services pursuant to restricted stock awards, Value			6,000	[3]	43,623		49,623
Issuance of common stock for accrued services pursuant to restricted stock awards, Shares	[3]		6,000,000
Stock compensation cost					36,825		36,825
Net loss						-7,704,843	-7,704,843
Stockholders' Equity, end of period, Value at Dec. 31, 2014			$241,186		$11,309,228	($22,154,175)	($10,603,761)
Stockholders' Equity, end of period, Shares at Dec. 31, 2014			241,186,179
[1]	12,020,445 shares issued at fair value at $0.0035 - $0.013 per share; 6,939,995 shares issued at fair value at $0.0035 - $0.012 per share; 23,090,000 shares issued at fair value at $0.0069 - $0.012 per share; 17,915,030 shares issued at fair value at $0.006 - $0.012 per share
[2]	44,783,036 shares issued at fair value at $0.0017 - $0.0041 per share; 54,697,929 shares issued at fair value at $0.00294 per share; 63,570,284 shares issued at fair value at $0.00045 per share
[3]	6,000,000 shares issued at fair value at $.0098 - $0.007 per share

STATEMENTS_OF_CASH_FLOWS

STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	($7,704,843)	($3,497,502)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	635	2,354
Stock compensation cost	36,825	101,755
Impairment of intangible assets	1,784	0
(Gain) loss on settlement of debt	-18,369	25,195
Gain on forgiveness of debt	0	-20,000
Notes payable issued for services	0	66,150
Amortization of debt discount and beneficial conversion feature recorded to interest expense	488,599	694,795
Loss on change in derivative liability	6,529,219	2,267,693
Changes in assets and liabilities:
(Increase) decrease in prepaid expenses	-66,835	9,130
Increase (decrease) in:
Accounts payable	-57,148	32,903
Accrued expenses and other current liabilities	130,790	61,472
NET CASH USED IN OPERATING ACTIVITIES	-659,343	-256,055
CASH FLOWS FROM INVESTING ACTIVITIES:
Patent expenditures	0	-200
NET CASH USED IN INVESTING ACTIVITIES	0	-200
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible notes payable	738,000	242,380
Proceeds from notes payable	0	11,000
Repayment of convertible notes payable	-74,592	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	663,408	253,380
NET INCREASE (DECREASE) IN CASH	4,065	-2,875
CASH, BEGINNING OF THE YEAR	11,382	14,257
CASH, END OF THE YEAR	$15,447	$11,382

1_Organization_and_Line_of_Bus

1. Organization and Line of Business	12 Months Ended
	Dec. 31, 2014
Notes
1. Organization and Line of Business	1.  ORGANIZATION AND LINE OF BUSINESS
	Organizational History
	Carbon Sciences, Inc. (the “Company”) was incorporated in the State of Nevada on August 25, 2006 as Zingerang, Inc.  On April 2, 2007, the Company changed its name to Carbon Sciences, Inc.
	Overview of Business
	The Company was initially in the business of offering real-time and interactive mobile communication services to businesses and consumers under the Zingerang trade name.  We are currently developing a technology to mass-produce graphene.  Graphene is a naturally occurring sheet of pure carbon that is only one atom thick.  It is flexible, transparent, impermeable to moisture, strong and highly conductive. Experts believe that graphene is a very versatile material that can enable new applications such as bendable touchscreen displays, rapid charge batteries, super-capacitors, low cost solar cells, extreme high-speed semiconductors, biosensors, as well as water purification.  We are currently researching and developing a cost-efficient process to manufacture commercial size sheets of graphene that can be fine-tuned with application-specific electrical and materials properties.  This research is done through a sponsored research agreement with the University of California, Santa Barbara (“UCSB”).
	Going Concern
	The accompanying financial statements have been prepared on a going concern basis of accounting, which contemplates continuity of operations, realization of assets and liabilities, and commitments in the normal course of business.  The accompanying financial statements do not reflect any adjustments that might result if the Company is unable to continue as a going concern.  The Company does not generate any revenue, and has negative cash flows from operations, which raise substantial doubt about the Company’s ability to continue as a going concern.  The ability of the Company to continue as a going concern is dependent upon, among other things, raising additional capital.  Since its inception through December 31, 2014, the Company has obtained funds primarily from the issuance of common stock and debt.  Management believes this funding will continue, and is continually seeking new investors.  Management believes the existing shareholders and lenders and prospective new investors will provide the additional cash needed to meet the Company’s obligations as they become due, and will allow the development of its core of business.

2_Summary_of_Significant_Accou

2. Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Notes
2. Summary of Significant Accounting Policies	2.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	This summary of significant accounting policies is presented to assist in understanding our financial statements.  The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity.  These accounting policies conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the financial statements.
	Revenue Recognition
	We will recognize revenue when services are performed, and at the time of shipment of products, provided that evidence of an arrangement exists, title and risk of loss have passed to the customer, fees are fixed or determinable, and collection of the related receivable is reasonably assured.  To date, we have had no revenues.
	Cash and Cash Equivalent
	We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents.
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements.  Significant estimates made in preparing these financial statements include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, the fair value of stock options and derivative liabilities.  Actual results could differ from those estimates.
	Property and Equipment
	Property and equipment are stated at cost, and are depreciated using the straight line method over the following estimated useful lives:
	Computer equipment	3 Years
	Machinery and equipment	7 Years
	Depreciation expense for the years ended December 31, 2014 and 2013 was $635 and $2,354, respectively.
	Patents and Impairment of Long-Lived Assets
	Our intangible assets that have finite lives have consisted of patents, the cost of which was amortized over the estimated legal life of 15 years.  During the year ended December 31, 2014, we reviewed the capitalized costs of our pending patents for impairment and determined that due to a change in our business plan, the carrying amount exceeded the fair value.  We impaired the entire carrying amount, and recognized an impairment loss of $1,784 during the year ended December 31, 2014.  As of December 31, 2014, we had no issued or pending patents.
	Fair Value of Financial Instruments
	Disclosures about fair value of financial instruments require disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value.  As of December 31, 2014 and 2013, the amounts reported for cash, accrued interest, accrued expenses and other current liabilities, and notes payable approximate fair value because of their short maturities.
	We adopted ASC Topic 820 (originally issued as SFAS 157, “Fair Value Measurements”) as of January 1, 2008 for financial instruments measured as fair value on a recurring basis.  ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements.
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  ASC Topic 820 established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.  The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1measurements) and the lowest priority to unobservable inputs (level 3 measurements).  These tiers include:
	·         Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;
	·         Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
	·         Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
	We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows at December 31, 2014 and 2013:
			Total	Level 1	Level 2	Level 3
	December 31, 2014:
	Derivative liability		$     9,476,605	$                 -	$                 -	$     9,476,605
	Convertible notes payable - current		654,199	-	-	654,199
	Convertible notes payable – long-term		61,117	-	-	61,117
	Total liabilities measured at fair value		$   10,191,921	$                 -	$                 -	$   10,191,921
	December 31, 2013:
	Derivative liability		$     2,811,962	$                 -	$                 -	$     2,811,962
	Convertible notes payable		492,904	-	-	492,904
	Total liabilities measured at fair value		$     3,304,866	$                 -	$                 -	$     3,304,866
	Derivative Liability
	We estimate the fair value of the derivative for the conversion feature of our convertible notes payable using the Black-Scholes pricing model at the inception of the debt, at the date of conversions to equity and at each reporting date, recording a derivative liability, debt discount and a gain or loss on change in derivative liability as applicable.  These estimates are based on multiple inputs, including the market price of our stock, interest rates, our stock price volatility, and variable conversion prices based on market prices as defined in the respective loan agreements.  These inputs are subject to significant changes from period to period; therefore, the estimated fair value of the derivative liability will fluctuate from period to period and the fluctuation may be material.
	Income (Loss) per Share Calculations
	The computation of basic income (loss) per common share is based on the weighted average number of shares outstanding during each year.
	The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus the common stock equivalents that would arise from the exercise of stock options and warrants outstanding, using the treasury stock method and the average market price per share during the year.  Common stock equivalents are not included in the diluted loss per share calculation when their effect is anti-dilutive.
	Since we had no dilutive effect of stock options and warrants for the years ended December 31, 2014 and 2013, our basic weighted average number of common shares outstanding is the same as our diluted weighted average number of common shares outstanding.
	Income Taxes
	We account for income taxes using the asset and liability method.  Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
	Research and Development
	Research and development costs are expensed as incurred.  Total research and development costs were $193,865 and $439 for the years ended December 31, 2014 and 2013, respectively.
	Advertising Costs
	We expense the cost of advertising and promotional materials when incurred.  We incurred no advertising costs for the years ended December 31, 2014 and 2013.
	Stock-Based Compensation
	Stock-based compensation is measured at the grant date based on the value of the award granted using the Black-Scholes option pricing model, and recognized over the period in which the award vests.  For stock awards no longer expected to vest, any previously recognized stock compensation expense is reversed in the period of termination.  The stock-based compensation expense is included in general and administrative expenses.
	Comprehensive Loss
	Comprehensive loss is the same as net loss for all years presented.
	Reclassifications
	Certain amounts in the prior years have been reclassified to conform to the current year presentation.
	Recently Issued Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this Update remove the financial statement distinction between development stage entities and other reporting entities from U.S. generally accepted accounting principles (“GAAP”).  In addition, the amendments eliminate the requirements for development stage entities to: (1) present inception-to-date information in the statements of income, cash flows and shareholder equity; (2) label the financial statements as those of a development stage entity; (3) disclose a description of the development stage activities in which the entity is engaged; and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	For public entities, the amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.  Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued.  We adopted the provisions of ASU No. 2014-10 during our third fiscal quarter ended September 30, 2014.
	In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 310-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.  The amendments in this Update provide guidance in GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures.  In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures.  The amendments are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.  Early application is permitted.  We have not determined the impact of the future adoption of the provisions of ASU No. 2014-15 on our financial statements.

3_Capital_Stock

3. Capital Stock	12 Months Ended
	Dec. 31, 2014
Notes
3. Capital Stock	3.  CAPITAL STOCK
	At December 31, 2014, the Company’s authorized stock consisted of 1,000,000,000 shares of common stock, with $0.001 par value.  The Company is also authorized to issue 20,000,000 shares of preferred stock, with a par value of $0.001 per share.  The rights, preferences, and privileges of the holders of the preferred stock will be determined by the Board of Directors prior to issuance of such shares.
	During the year ended December 31, 2014, we issued a total of 169,051,249 shares of common stock at fair value.  We issued 163,051,249 shares in conversion of $230,385 of convertible promissory notes, accrued interest payable of $9,987, derivative liability of $602,576 and reduction of debt discount of $47,639. We recognized a gain of $18,369 on the conversion of the notes.  We also issued a total of 6,000,000 shares of common stock for accrued consulting services of $49,623 pursuant to a restricted stock grant.
	During the year ended December 31, 2013, we issued a total of 59,965,470 shares of common stock at fair value in conversion of $219,934 of convertible promissory notes, plus accrued interest payable of $5,517. We recognized a loss of $33,277 on the conversion of the notes.  We also issued a total of 592,780 shares of common stock pursuant to a price protection clause in a prior year agreement to issue shares for cash.  These shares were recorded at par value.

4_Stock_Options_Warrants_and_R

4. Stock Options, Warrants and Restricted Stock Awards	12 Months Ended
	Dec. 31, 2014
Notes
4. Stock Options, Warrants and Restricted Stock Awards	4.  STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK AWARDS
	Stock Options
	As of December 31, 2014, our Board of Directors granted a total of 14,100,000 non-qualified stock options to purchase 14,100,000 shares of common stock to our employees, officers, and consultants.  Stock-based compensation expense included in general and administrative expense was $36,825 and $101,755 for the years ended December 31, 2014 and 2013, respectively.
	In September 2013, the Board of Directors granted a total of 14,000,000 non-qualified stock options to our former chief executive officer and our current chief executive officer to purchase a total of 14,000,000 shares at an exercise price of $0.006 per share.  The options vest over a period of 25 months beginning in October 2013 and are exercisable for a period of seven years from the date of grant.  As of December 31, 2014, unrecognized stock-based compensation expense was approximately $28,000.
	A summary of the Company’s stock option awards as of December 31, 2014, and changes during the years ended December 31, 2014 and 2013 are as follows:
		Shares	Weighted Average Exercise Price		Weighted Average Remaining Contract Term (Years)	Aggregate Intrinsic Value
	Outstanding at December 31, 2012	1,137,500	$	2.39
	Granted	14,000,000	$	0.006
	Exercised	-	$	-
	Forfeited or expired	-1,037,500	$	2.44
	Outstanding at December 31, 2013	14,100,000	$	0.019	6.72	$   56,000
	Granted	-	$	-
	Exercised	-	$	-
	Forfeited or expired	-	$	-
	Outstanding at December 31, 2014	14,100,000	$	0.019	5.72	$   -
	Exercisable at December 31, 2014	8,500,000	$	0.03	5.72	$  -
	The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on our closing stock price of $0.0045 as of December 31, 2014, which would have been received by the holders of in-the-money options had the option holders exercised their options as of that date.
	Warrants
	As of December 31, 2014, the Company had 460,000 common stock purchase warrants outstanding, with an exercise price of $0.50 per share and expiring on various dates in 2017 and 2018.
	Restricted Stock Awards
	On September 12, 2013 and as amended on October 24, 2013, two consultants were each granted restricted stock awards for 14,000,000 shares of our common stock (the “RSAs”).  The shares were to vest upon reaching certain defined milestones related to our development and construction of a gas-to-liquid plant.  Total compensation deferred at December 31, 2013 to be recognized as the shares vest, calculated using the closing market price of our common stock on the date of grant, was $137,200.
	During the year ended December 31, 2014, 3,000,000 shares vested for each of the two consultants and we recognized total compensation expense of $49,623.  We have discontinued our development of the gas-to-liquid plant involving the consultants.  Therefore, there will be no further vesting of shares and recognition of compensation expense under RSAs.

5_Notes_Payable

5. Notes Payable	12 Months Ended
	Dec. 31, 2014
Notes
5. Notes Payable	5.  NOTES PAYABLE
	During the year ended December 31, 2013, the Company issued short-term promissory notes totaling $77,620: $11,000 for cash, $40,470 in payment of accounts payable and $26,150 issued for services.  All of these notes were subsequently exchanged for convertible notes payable (Note 6) during the year ended December 31, 2013.

6_Convertible_Notes_Payable

6. Convertible Notes Payable	12 Months Ended
	Dec. 31, 2014
Notes
6. Convertible Notes Payable	6.  CONVERTIBLE NOTES PAYABLE
	Institutional Lender
	We entered into two securities purchase agreements on September 19, 2012 and December 12, 2012, for the issuance of two 8% convertible promissory notes in the aggregate principal amount of $75,000.  We recorded a debt discount of $75,000 related to the conversion feature of the notes, along with a derivative liability at inception.
	The notes were convertible into shares of our common stock at a price equal to a variable conversion price of 58% multiplied by a defined market price, representing a discount of 42%.  The market price was defined as the average of the lowest three (3) trading prices for our common stock during a ten trading day period ending on the latest complete trading day prior to the conversion date.  During the year ended December 31, 2013 both notes were converted into shares of our common stock, extinguishing a total of $75,000 in principal and $3,000 in accrued interest.
	We subsequently entered into three additional securities purchase agreements with the same lender on July 8, 2013, September 16, 2013 and January 6, 2014 for the issuance of three 8% promissory notes in the aggregate principal amounts of $42,500, $32,500 and $63,000, respectively.  The notes are convertible into shares of our common stock at a price equal to a variable conversion price of $58% multiplied by a defined market price, representing a discount of 42%.  The market price is defined as the average of the lowest three trading prices for our common stock during a ten trading day period ending on the latest complete trading day prior to the conversion date.
	During the year ended December 31, 2014, the July 8, 2013 note was fully converted into shares of our common stock, extinguishing a total of $42,500 in principal and $1,700 in accrued interest.  During the year ended December 31, 2014, amortization of debt discount was recorded to interest expense in the amount of $15,399.
	During the year ended December 31, 2014, the September 16, 2013 note was fully converted into shares of our common stock, extinguishing a total of $32,500 in principal and $1,300 in accrued interest.  During the year ended December 31, 2014, amortization of debt discount was recorded to interest expense in the amount of $19,973.
	During the year ended December 31, 2014, the January 6, 2014 note was partially converted into shares of our common stock, extinguishing a total of $16,325 in principal.  We paid in cash the remaining $46,675 in principal and $18,325 in accrued interest and early payment penalties.
	We recorded a debt discount of $63,000 related to the conversion feature of the January 6, 2014 note, along with a derivative liability at inception.  During the year ended December 31, 2014, amortization of the debt discount was recorded to interest expense in the amount of $63,000.
	Securities Purchase Agreement - $299,212
	On December 12, 2012, we exchanged certain promissory notes in the aggregate amount of $327,500 for convertible promissory notes.  We entered into securities purchase agreements for the sale of 10% convertible promissory notes in the aggregate principal amount of $327,500, which were convertible into shares of our common stock at a conversion price equal to (a) the lesser of $0.54 per share or (b) 50% of the lowest trade price recorded on any trade date after the effective date, or (c) the lowest effective price per share granted to any person after the effective date. The notes were to mature one year from the effective date of the note.  We recorded a debt discount of $327,500 related to the conversion feature of the note, along with a derivative liability at inception.  During 2013, the principal sum of $62,000, plus accrued interest was transferred to another investor, and a total of $36,057 principal and $886 accrued interest were converted into shares of our common stock.  During 2013, the remaining debt discount of $312,740 was amortized to interest expense.
	Effective October 24, 2013, the remaining principal balance of the notes discussed in the preceding paragraph totaling $291,443 and accrued interest of $7,769 were combined in a new 10% convertible promissory note in the aggregate amount of $299,212, which matured on October 24, 2014.  The new note is convertible into shares of our common stock at a conversion price equal to (a) the lesser of $0.006 per share or (b) 50% of the lowest trade price recorded on any trade date after the effective date, or (c) the lowest effective price per share granted to any person after the effective date.  During the year ended December 31, 2013, a total of $16,750 principal and $1,631 accrued interest were converted into shares of our common stock, resulting in a principal balance of $282,462 payable at December 31, 2013.  During the year ended December 31, 2014, a total of $49,450 principal and $6,986 accrued interest were converted into shares of our common stock, resulting in a principal balance of $233,012 payable at December 31, 2014.  The maturity date of the note was extended to June 30, 2015.
	Securities Purchase Agreements - Services of $244,452
	On December 31, 2012, we entered into convertible promissory notes with three individuals in exchange for services rendered in the aggregate amount of $244,452, including $185,852 with the Chairman of our Board of Directors and our former Chief Executive Officer.  We entered into securities purchase agreements for the sale of 5% convertible promissory notes in the principal amount of $244,452, which are convertible into shares of our common stock at a conversion price equal to the lesser of $0.20 per share or the closing price per share of common stock recorded on the trading day immediately preceding the date of conversion.  The notes mature on December 31, 2015.  We recorded a debt discount of $237,742 related to the conversion feature of the notes, along with a derivative liability at inception.  During the years ended December 31, 2014 and 2013, total amortization was recorded to interest expense in the amounts of $120,958 and $118,993, respectively.
	Securities Purchase Agreement - $100,000
	During 2013, we received total proceeds of $40,000 pursuant to a securities purchase agreement for the sale of 10% convertible promissory notes in the aggregate principal amount of $100,000.  The notes are convertible into shares of our common stock at a price equal to a variable conversion price of the lesser of $0.09 per share or fifty percent (50%) of the lowest trade price recorded after the effective date.  The notes were to mature one year from their effective date.  The maturity dates have been extended to June 30, 2015.  We recorded a debt discount of $40,000 related to the beneficial conversion feature of the notes.  During the years ended December 31, 2014 and 2013, total amortization was recorded to interest expense in the amounts of $8,849 and $31,151, respectively.
	Securities Purchase Agreement - $335,000
	On October 8, 2012, we received proceeds of $75,000 pursuant to a securities purchase agreement for the sale of 10% convertible promissory notes in aggregate principal amount of $335,000 with a 10% Original Issue Discount (OID) of $35,000 (the “$335,000 SPA”).  The principal amount of $83,750 outstanding on the note as of December 31, 2012 included the payment of $75,000 plus the unamortized original issue discount of $8,750.  We recorded a debt discount of $54,843 related to the conversion feature of the note and $8,750 related to the original issue discount, along with a derivative liability at inception.  During 2013, the principal sum of $80,844 was converted into shares of our common stock.  The remaining principal balance of $2,906 and accrued interest payable of $4,188 were transferred to and included in a new note payable to this lender.  During 2013, the balance of the debt discount of $43,283 was fully amortized to interest expense.
	On February 27, 2013, we received additional proceeds of $25,000 on this securities purchase agreement, with an original issue discount of $2,917 for total principal owed of $27,917.  We recorded a debt discount of $25,403 related to the conversion feature of the note and the original issue discount, along with a derivative liability at inception.  Total principal of $7,239 was also transferred from another note to this note.  During the year ended December 31, 2013, total principal balance of $11,284 was converted into shares of our common stock and total amortization of debt discount was recorded to interest expense in the amount of $23,266.  During the year ended December 31, 2014, the remaining principal balance of $25,122 and accrued interest of $1,250 were converted into shares of our common stock and the remaining debt discount of $2,137 was amortized to interest expense.
	On December 10, 2013, we received proceeds of $25,000 pursuant to the $335,000 SPA, with an original issue discount of $4,313 for total principal owed of $29,313.  We recorded a debt discount of $29,313 related to the conversion feature of the note and the original issue discount, along with a derivative liability at inception.   During the year ended December 31, 2014, the note was fully converted into shares of our common stock, extinguishing $29,313 in principal.  During the year ended December 31, 2014, amortization of debt discount to interest expense was $27,627.
	On February 20, 2014, we received proceeds of $30,000 pursuant to the $335,000 SPA, with an original issue discount of $5,175 for total principal owed of $35,175.  We recorded a debt discount of $35,175 related to the conversion feature of the note and the original issue discount, along with a derivative liability at inception.  During the year ended December 31, 2014, the note was fully converted into shares of our common stock, extinguishing $35,175 in principal.  During the year ended December 31, 2014, amortization of debt discount to interest expense was $35,175.
	On June 25, 2014, we received proceeds of $25,000 pursuant to the $335,000 SPA, with an original issue discount of $2,917 for total principal owed of $27,917.  During the year ended December 31, 2014, the note was fully paid in cash, extinguishing $27,917 in principal.  During the year ended December 31, 2014, amortization of debt discount to interest expense was $27,917.
	If the notes issued under the $335,000 SPA are repaid before 90 days, the interest rate will be zero percent (0%), otherwise a one-time interest rate of five percent (5%) will be applied to the principal sums outstanding.  The notes are convertible into shares of our common stock at a price equal to the lesser of $0.72 or 70% of the lowest trading price in the 25 trading days prior to the conversion.  The notes mature one year from the effective date of each advance.
	Securities Purchase Agreement – Accounts Payable of $29,500
	On March 14, 2013, we entered into a convertible promissory note in exchange for accounts payable in the amount of $29,500.  We entered into securities purchase agreements for the sale of a 5% convertible promissory note in the principal amount of $29,500, which is convertible into shares of our common stock at a conversion price equal to the lesser of $0.15 per share or the closing price per share of common stock recorded on the trading day immediately preceding the date of conversion.  The note matures two years from its effective date, or March 14, 2015.
	Securities Purchase Agreement - $97,000
	On May 29, 2013, we exchanged $97,000 in demand promissory notes for convertible promissory notes pursuant to a securities purchase agreement for the sale of a 10% convertible promissory note in the aggregate principal amount of $97,000.  The note is convertible into shares of our common stock at a price equal to a conversion price of the lesser of $0.028 per share or fifty percent (50%) of the lowest trade price recorded after the effective date.  The note matured six months from the effective date.  The maturity date of the note was extended to June 30, 2015.  We recorded a debt discount of $97,000 related to the beneficial conversion feature of the note.  During 2013, the debt discount of $97,000 was fully amortized to interest expense.
	Securities Purchase Agreement – Services of $25,000
	On June 4, 2013, we entered into a convertible promissory note with a former member of our Board of Directors in exchange for services rendered in the amount of $25,000. We entered into securities purchase agreements for the sale of a 5% convertible promissory note in the principal amount of $25,000, which is convertible into shares of common stock of the Company at a conversion price equal to the lesser of $0.035 per share or the closing price per share of common stock recorded on the trading day immediately preceding the date of conversion.  The note matures three years from its effective date, or June 4, 2016.
	Securities Purchase Agreement – Chief Executive Officer Services of $15,000
	On May 31, 2013, we entered into a convertible promissory note in exchange for services rendered by our Chief Executive Officer in the amount of $15,000.  We entered into securities purchase agreements for the sale of a 5% convertible promissory note in the principal amount of $15,000, which is convertible into shares of our common stock at a conversion price equal to the lesser of $0.04 per share or the closing price per share of common stock recorded on the trading day immediately preceding the date of conversion.  The note was to mature two years from its effective date.  Subsequently in 2013, the Chief Executive Officer contributed the note to capital.
	Securities Purchase Agreement - $5,000 Exchanged Note
	On September 6, 2013, we exchanged a $5,000 promissory note for a convertible promissory note pursuant to a securities purchase agreement for the sale of a 10% convertible promissory note in the aggregate principal amount of $5,000.  The note is convertible into shares of our common stock at a price equal to a conversion price of the lesser of $0.0042 per share or fifty percent (50%) of the lowest trade price recorded after the effective date.  The note matures on June 30, 2015.  We recorded a debt discount of $2,536 related to the beneficial conversion feature of the note, along with a derivative liability at inception.  During the years ended December 31, 2014 and 2013, total amortization was recorded to interest expense in the amounts of $1,459 and $1,077, respectively.
	Securities Purchase Agreement - $250,000
	On October 8, 2012, we entered into to a securities purchase agreement for the sale of 10% convertible promissory notes in aggregate principal amount of $250,000.  The notes are convertible into shares of common stock of the Company at a price equal to the lesser of $0.006 or 50% of the lowest trade price subsequent to the effective date of the note and prior to the conversion.  The notes matured six months from the effective date of each advance.  The maturity dates of the notes were extended to June 30, 2015.
	The lender previously advanced a total of $11,000 in August and September 2013 that was transferred to this agreement.  We recorded a debt discount of $11,000 along with a derivative liability upon transfer.  During the years ended December 31, 2014 and 2013, amortization of debt discount to interest expense was $5,863 and $5,137, respectively.
	On October 21, 2013, we received additional proceeds of $22,000 on this securities purchase agreement.  We recorded a debt discount of $22,000 along with a derivative liability at inception.  During the years ended December 31, 2014 and 2013, amortization of debt discount to interest expense was $13,418 and $8,582, respectively.
	On November 22, 2013, we received additional proceeds of $25,000 on this securities purchase agreement.  We recorded a debt discount of $25,000 along with a derivative liability at inception.  During the years ended December 31, 2014 and 2013, amortization of debt discount to interest expense was $19,613 and $5,387, respectively.
	Securities Purchase Agreement - $500,000
	On April 18, 2014, we entered into a securities purchase agreement for the sale of 10% convertible promissory notes in aggregate principal amount of $500,000 (the “$500,000 SPA”).  The advance amounts received are at the lender’s discretion.  The notes are convertible into shares of our common stock at a price per share equal to the lesser of: $0.003; 50% of the lowest trade price subsequent to the effective date of the note and prior to the conversion; or the lowest effective price per share granted to any person or entity to acquire common stock subsequent to the effective date of the note.  The notes mature eighteen months from the effective date of each advance.
	On April 18, 2014, we received proceeds of $60,000 pursuant to the $500,000 SPA.  We recorded a debt discount of $60,000 related to the conversion feature of the note, along with a derivative liability at inception.  During the year ended December 31, 2014, amortization of debt discount was recorded to interest expense in the amount of $28,139, resulting in a remaining discount of $31,861 at December31, 2014.
	On May 20, 2014, we received proceeds of $45,000 pursuant to the $500,000 SPA.  We recorded a debt discount of $45,000 related to the conversion feature of the note, along with a derivative liability at inception.  During the year ended December 31, 2014, amortization of debt discount was recorded to interest expense in the amount of $18,443, resulting in a remaining discount of $26,557 at December 31, 2014.
	On June 30, 2014, we received proceeds of $200,000 pursuant to the $500,000 SPA.  We recorded a debt discount of $200,000 related to the conversion feature of the note, along with a derivative liability at inception.  During the year ended December 31, 2014, amortization of debt discount was recorded to interest expense in the amount of $67,153, resulting in a remaining discount of $132,847 at December 31, 2014.
	On July 18, 2014, we received proceeds of $25,000 pursuant to the $500,000 SPA.  We recorded a debt discount of $25,000 related to the conversion feature of the note, along with a derivative liability at inception.  During the year ended December 31, 2014, amortization of debt discount was recorded to interest expense in the amount of $7,559, resulting in a remaining discount of $17,441 at December 31, 2014.
	On August 6, 2014, we received proceeds of $65,000 pursuant to the $500,000 SPA.  We recorded a debt discount of $65,000 related to the conversion feature of the note, along with a derivative liability at inception.  During the year ended December 31, 2014, amortization of debt discount was recorded to interest expense in the amount of $17,404, resulting in a remaining discount of $47,596 at December 31, 2014.
	On August 18, 2014, we received proceeds of $25,000 pursuant to the $500,000 SPA.  We recorded a debt discount of $25,000 related to the conversion feature of the note, along with a derivative liability at inception.  During the year ended December 31, 2014, amortization of debt discount was recorded to interest expense in the amount of $6,148, resulting in a remaining discount of $18,852 at December 31, 2014.
	On September 9, 2014, we received proceeds of $56,000 pursuant to the $500,000 SPA.  We recorded a debt discount of $56,000 related to the conversion feature of the note, along with a derivative liability at inception.  During the year ended December 31, 2014, amortization of debt discount was recorded to interest expense in the amount of $11,569, resulting in a remaining discount of $44,431 at December31, 2014.
	On October 8, 2014, we received proceeds of $24,000 pursuant to the $500,000 SPA.  We recorded a debt discount of $24,000 related to the conversion feature of the note, along with a derivative liability at inception.  During the year ended December 31, 2014, amortization of debt discount was recorded to interest expense in the amount of $3,679, resulting in a remaining discount of $20,321 at December 31,2014.
	Securities Purchase Agreement - $500,000
	On October 1, 2014, we entered into a securities purchase agreement for the sale of 10% convertible promissory notes in aggregate principal amount of $500,000 (the “October 2014 $500,000 SPA”).  The advance amounts received are at the lender’s discretion.  The notes are convertible into shares of our common stock at a price per share equal to the lesser of: $0.003; 50% of the lowest trade price subsequent to the effective date of the note and prior to the conversion; or the lowest effective price per share granted to any person or entity to acquire common stock subsequent to the effective date of the note.  The notes mature eighteen months from the effective date of each advance.
	On October 1, 2014, we received proceeds of $65,000 pursuant to the October 2014 $500,000 SPA.  We recorded a debt discount of $65,000 related to the conversion feature of the note, along with a derivative liability at inception.  During the year ended December 31, 2014, amortization of debt discount was recorded to interest expense in the amount of $10,794, resulting in a remaining discount of $54,206 at December 31, 2014.
	On November 7, 2014, we received proceeds of $30,000 pursuant to the October 2014 $500,000 SPA.  We recorded a debt discount of $30,000 related to the conversion feature of the note, along with a derivative liability at inception.  During the year ended December 31, 2014, amortization of debt discount was recorded to interest expense in the amount of $2,962, resulting in a remaining discount of $27,038 at December 31, 2014.
	On December 9, 2014, we received proceeds of $25,000 pursuant to the October 2014 $500,000 SPA.  We recorded a debt discount of $25,000 related to the conversion feature of the note, along with a derivative liability at inception.  During the year ended December 31, 2014, amortization of debt discount was recorded to interest expense in the amount of $1,004, resulting in a remaining discount of $23,996 at December 31, 2014.
	For purpose of determining the fair market value of the derivative liability, we used the Black Scholes option valuation model.
	The significant assumptions used in the Black Scholes valuation of the derivative liability at December 31, 2014 are as follows:
	Stock price on the valuation date		$0.00
	Conversion price for the debt		$0.0045 - $0.005
	Dividend yield		0	%
	Years to maturity		0.89 - 1.44
	Risk free rate		.14% - .46	%
	Expected volatility		176.60% - 326.86	%
	The value of the derivative liability balance at December 31, 2014 and 2013 was $9,476,605 and $2,811,962, respectively.  These assumptions are subject to significant changes and market fluctuations from period to period; therefore, the estimated fair value of the derivative liability will fluctuate from period to period and the fluctuation may be material.  Based on the assumptions used to estimate the fair value of the derivate liability at December 31, 2014 and assuming all lenders convert the notes payable at the December 31, 2014 conversion prices, the Company would have insufficient authorized shares of common stock to complete the debt conversions.
	During the years ended December 31, 2014 and 2013, the Company had the following activity in its derivative liability account:
	Derivative liability at December 31, 2012	$           753,971
Elimination of liability on conversion	-430,781
Change in fair value	2,488,772
Derivative liability at December 31, 2013	2,811,962
Elimination of liability on conversion	-602,576
Change in fair value	7,267,219
Derivative liability at December 31, 2014	$         9,476,605
The total gain on settlement of debt related to the conversion of notes payable into shares of our common stock was $18,369 for the year ended December 31, 2014.  The total loss on settlement of debt related to the conversion of notes payable into shares of our common stock was $25,195 for the year ended December 31, 2013.

7_Research_Agreement

7. Research Agreement	12 Months Ended
	Dec. 31, 2014
Notes
7. Research Agreement	7.  RESEARCH AGREEMENT
	On June 18, 2014, the Company entered into a Sponsored Research Agreement (the “SRA”) with the University of California, Santa Barbara campus (“UCSB”), pursuant to which UCSB will perform research work for the mutual benefit of UCSB and the Company.  The purpose of the SRA includes the development of a low-cost and scalable method to produce large-area graphene for transparent electrode applications.  The term of the SRA commenced on July 1, 2014 and will expire on June 30, 2015.  The total cost to the Company will not exceed $387,730, as determined on a cost-reimbursement basis.  Payment of the total cost has been made and is payable in installments as follows:
	$200,000 on or before July 1, 2014
	$62,577 on October 1, 2014
	$62,577 On January 1, 2015
	$62,576 on April 1, 2015
	The Company amortizes the payments over the life of the contract.  As of December 31, 2014, $68,712 was included in prepaid expenses related to the contract and $193,865 was included in research and development expenses related to the contract.

8_Supplemental_Statement_of_Ca

8. Supplemental Statement of Cash Flows Information	12 Months Ended
	Dec. 31, 2014
Notes
8. Supplemental Statement of Cash Flows Information	8.  SUPPLEMENTAL STATEMENT OF CASH FLOWS INFORMATION
	During the years ended December 31, 2014 and 2013, we paid no amounts for income taxes.
	During the years ended December 31, 2014 and 2013, we paid interest of $18,983 and $4,333, respectively.
	During the year ended December 31, 2014, the Company had the following non-cash investing and financing activities:
	The Company issued a total of 163,051,249 shares of common stock in conversion of $230,385 in convertible notes payable, plus $9,987 of accrued interest payable, increasing common stock by $163,051, increasing additional paid-in capital by $613,889, decreasing debt discount by $47,639 and decreasing derivative liability by $602,576.
	The Company increased debt discount and derivative liability by $738,000 for the issuance of new convertible debt.
	The Company issued a total of 6,000,000 shares of common stock, which vested pursuant to RSAs, in payment of accrued expenses of $49,623, increasing common stock by $6,000 and additional paid-in capital of $43,623.
	During the year ended December 31, 2013, we had the following non-cash investing and financing activities:
	We issued a total of 59,965,470 shares of common stock in conversion of $219,934 in convertible notes payable, plus $5,517 of accrued interest payable, increasing common stock by $59,965, increasing additional paid-in capital by $540,325, decreasing debt discount by $55,942 and decreasing derivative liability by $430,781.
	We exchanged notes payable of $82,620 for convertible notes payable.
	We issued 592,780 shares of common stock pursuant to a price protection clause in a prior year agreement to issue shares for cash, increasing common stock and decreasing additional paid-in capital by $593.
	We increased additional paid-in capital and decreased accrued interest, notes payable by $7,175 to record the contribution of related party accrued interest to capital.
	We increased additional paid-in capital and beneficial conversion feature by $138,951 for the beneficial conversion feature related to new notes and decreased additional paid-in capital by $15,571, increased derivative liability by $6,585 and decreased debt discount by $8,986.
	We issued convertible notes payable for accounts payable of $29,500.
	We issued notes payable for accounts payable of $40,470.
	We decreased convertible notes payable and increased additional paid-in capital by $15,000 for the note contributed to capital.
	We decreased accrued interest payable and increased convertible notes payable by $11,955.

9_Income_Taxes

9. Income Taxes	12 Months Ended
	Dec. 31, 2014
Notes
9. Income Taxes	9.  INCOME TAXES
	A reconciliation of the income tax provision (benefit) that would result from applying a combined U.S. federal and state rate of 43% to loss before income taxes with the provision (benefit) for income taxes presented in the financial statements is as follows:
		Years Ended December 31,
		2014	2013
	Income tax benefit at statutory rate	$      (3,313,100)	$      (1,503,900)
	State income taxes, net of federal benefit	-300	-300
	Depreciation	200	800
	Non deductible stock deductions	3,046,900	1,335,100
	Other	-3,000	36,800
	Valuation allowance	269,300	131,500
		$                      -	$                      -
	Deferred tax assets (liabilities) are comprised of the following:
		December 31,
		2014	2013
	Deferred tax assets:
	Net operating loss carryforward	$3,471,200	$3,204,900
	Research and development credit carryforward	100,100	100,000
	Related party accrued expenses	8,800	4,300
	Accrued compensated absences	600	2,400
	Deferred tax liability:
	Depreciation	-	-200
	Valuation allowance	-3,580,700	-3,311,400
		$-	$-
	The ultimate realization of our deferred tax assets is dependent, in part, upon the tax laws in effect, our future earnings, and other events.  As of December 31, 2014, we recorded a valuation allowance of $3,580,700 against net current deferred tax.  In recording the valuation allowance, we were unable to conclude that it is more likely than not that our deferred tax assets will be realized.
	As of December 31, 2014, we had a net operating loss carryforward available to offset future taxable income of approximately $8,072,000, which begins to expire at dates that have not been determined.  If substantial changes in the Company’s ownership should occur, there would be an annual limitation of the amount of the net operating loss carryforward that could be utilized.
	We perform a review of our material tax positions in accordance with recognition and measurement standards established by authoritative accounting literature, which requires a company to determine whether it is more likely than not that a tax position will be sustained upon examination based upon the technical merits of the position.  If the more-likely-than-not threshold is met, a company must measure the tax position to determine the amount to recognize in the financial statements.  Based upon our review and evaluation, during the years ended December 31, 2014 and 2013, we concluded the Company had no unrecognized tax benefit that would affect its effective tax rate if recognized.
	We file income tax returns in the U.S. federal jurisdiction and in the state of California.  With few exceptions, we are no longer subject to U.S. federal, state or local income tax examinations by tax authorities for years before 2011.
	We classify any interest and penalties arising from the underpayment of income taxes in our statements of operations and comprehensive loss in other income (expense).  As of December 31, 2014 and 2013, we had no accrued interest or penalties related to uncertain tax positions.

10_Related_Party_Transactions

10. Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Notes
10. Related Party Transactions	10.  RELATED PARTY TRANSACTIONS
	See Notes 5 and 6 for discussion of notes payable and convertible notes payable with related parties, including multiple lenders who are also shareholders of the Company.
	On December 12, 2012, we entered into a convertible note with the Chairman of our Board of Directors and our former Chief Executive Officer in exchange for services valued at $185,852.  The principal balance of this related party note was $185,852 as of December 31, 2014 and 2013, with accrued interest payable of $18,585 and $9,293 as of December 31, 2014 and 2013, respectively.  The note matures on December 31, 2015.
	On June 4, 2013, we entered into a convertible note with a former member of our Board of Directors in exchange for services valued at $25,000.  As of December 31, 2014 and 2013, the principal balance of this related party note was $25,000, with accrued interest payable of $1,969 and $719, respectively.  The note matures on June 4, 2016.
	On May 31, 2013, we entered into a convertible promissory note in exchange for services rendered by our Chief Executive Officer in the amount of $15,000.   Subsequently in 2013, the Chief Executive Officer contributed the note to capital and we decreased convertible notes payable and increased additional paid-in capital by $15,000.
	In 2013, we increased additional paid-in capital and decreased accrued interest, notes payable by $7,175 to record the contribution of related party accrued interest to capital.

11_Operating_Lease

11. Operating Lease	12 Months Ended
	Dec. 31, 2014
Notes
11. Operating Lease	11.  OPERATING LEASE
	We extended our facility lease for a period of five years, expiring on September 30, 2017.  The base rent for the period of October 1, 2012 to September 30, 2013 is $2,884 per month, and for the remaining period commencing on October 1, 2013 to September 30, 2017 the base rent will be $2,971 per month. Rent expense for the years ended December 31, 2014 and 2013 was $58,306 and $53,045, respectively.

12_Consulting_Agreements

12. Consulting Agreements	12 Months Ended
	Dec. 31, 2014
Notes
12. Consulting Agreements	12.  CONSULTING AGREEMENTS
	We have a written consulting agreement dated May 31, 2013 with William Beifuss, Jr., our Chief Executive Officer, President and Acting Chief Financial Officer, for the payment of monthly compensation of $5,000 per month beginning in June 2013.  The agreement may be cancelled by either party with 30 days notice.
	On December 5, 2014, we entered into an agreement for consulting services with Mitr Consulting Corporation (the “Consultant”).  The Consultant will provide services to the Company in the development of technology for the manufacture of graphene and related applications.  The Consultant will be paid a monthly fee of $5,000.  The agreement will continue on a month-to-month basis until terminated by either party with a 30-day prior written notice.

12_Subsequent_Events

12. Subsequent Events	12 Months Ended
	Dec. 31, 2014
Notes
12. Subsequent Events	12.  SUBSEQUENT EVENTS
	Management has evaluated subsequent events according to the requirements of ASC TOPIC 855, and has reported the following:
	On January 5, 2015, the Company formed Transphene, Inc., a Nevada corporation (“Transphene”), of which the Company owns 50% of the total issued and outstanding capital stock.  The remaining 50% is owned by Dr. Kaustav Banerjee (“Banerjee”), a director and Chief Technical Officer of Transphene.  Transphene is formed to conduct the new business of the Company developing a technology to mass produce graphene from natural gas.  In consideration for its interest in Transphene, the Company assigned the intellectual property rights acquired by the Company from its Research Agreement with the Regents of the University of California, dated June 18, 2014, to Transphene.  The Company and Banerjee also entered into a Shareholders’ Agreement pursuant to which the Company and Banerjee agreed to (i) vote their shares to elect Mr. William E. Beifuss and Banerjee as the directors of Transphene and (ii) not sell or transfer shares until the selling shareholder first offers its shares to the other shareholder.
	In January 2015, we made the third payment of $62,577 due under the SRA discussed in Note 7.
	Subsequent to December 31, 2014, we issued lenders a total of 24,790,746 shares of our common stock for the conversion of debt principal of $9,200 and accrued interest of $1,956.
	We received proceeds of $92,000 in January 2015 and $30,000 in February 2015 from convertible promissory notes payable.
	Subsequent to December 31, 2014, the maturity dates of certain convertible promissory notes were extended to various dates in 2015.

2_Summary_of_Significant_Accou1

2. Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Policies
Revenue Recognition	Revenue Recognition
	We will recognize revenue when services are performed, and at the time of shipment of products, provided that evidence of an arrangement exists, title and risk of loss have passed to the customer, fees are fixed or determinable, and collection of the related receivable is reasonably assured.  To date, we have had no revenues.
Cash and Cash Equivalent	Cash and Cash Equivalent
	We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents.
Use of Estimates	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements.  Significant estimates made in preparing these financial statements include the estimate of useful lives of property and equipment, the deferred tax valuation allowance, the fair value of stock options and derivative liabilities.  Actual results could differ from those estimates.
Property and Equipment	Property and Equipment
	Property and equipment are stated at cost, and are depreciated using the straight line method over the following estimated useful lives:
	Computer equipment	3 Years
	Machinery and equipment	7 Years
	Depreciation expense for the years ended December 31, 2014 and 2013 was $635 and $2,354, respectively.
Patents and Impairment of Long-lived Assets	Patents and Impairment of Long-Lived Assets
	Our intangible assets that have finite lives have consisted of patents, the cost of which was amortized over the estimated legal life of 15 years.  During the year ended December 31, 2014, we reviewed the capitalized costs of our pending patents for impairment and determined that due to a change in our business plan, the carrying amount exceeded the fair value.  We impaired the entire carrying amount, and recognized an impairment loss of $1,784 during the year ended December 31, 2014.  As of December 31, 2014, we had no issued or pending patents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	Disclosures about fair value of financial instruments require disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value.  As of December 31, 2014 and 2013, the amounts reported for cash, accrued interest, accrued expenses and other current liabilities, and notes payable approximate fair value because of their short maturities.
	We adopted ASC Topic 820 (originally issued as SFAS 157, “Fair Value Measurements”) as of January 1, 2008 for financial instruments measured as fair value on a recurring basis.  ASC Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted in the United States, and expands disclosures about fair value measurements.
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.  ASC Topic 820 established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.  The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1measurements) and the lowest priority to unobservable inputs (level 3 measurements).  These tiers include:
	·         Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;
	·         Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and
	·         Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
	We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows at December 31, 2014 and 2013:
			Total	Level 1	Level 2	Level 3
	December 31, 2014:
	Derivative liability		$     9,476,605	$                 -	$                 -	$     9,476,605
	Convertible notes payable - current		654,199	-	-	654,199
	Convertible notes payable – long-term		61,117	-	-	61,117
	Total liabilities measured at fair value		$   10,191,921	$                 -	$                 -	$   10,191,921
	December 31, 2013:
	Derivative liability		$     2,811,962	$                 -	$                 -	$     2,811,962
	Convertible notes payable		492,904	-	-	492,904
	Total liabilities measured at fair value		$     3,304,866	$                 -	$                 -	$     3,304,866
Derivative Liability	Derivative Liability
	We estimate the fair value of the derivative for the conversion feature of our convertible notes payable using the Black-Scholes pricing model at the inception of the debt, at the date of conversions to equity and at each reporting date, recording a derivative liability, debt discount and a gain or loss on change in derivative liability as applicable.  These estimates are based on multiple inputs, including the market price of our stock, interest rates, our stock price volatility, and variable conversion prices based on market prices as defined in the respective loan agreements.  These inputs are subject to significant changes from period to period; therefore, the estimated fair value of the derivative liability will fluctuate from period to period and the fluctuation may be material.
Income (loss) Per Share Calculations	Income (Loss) per Share Calculations
	The computation of basic income (loss) per common share is based on the weighted average number of shares outstanding during each year.
	The computation of diluted earnings per common share is based on the weighted average number of shares outstanding during the year plus the common stock equivalents that would arise from the exercise of stock options and warrants outstanding, using the treasury stock method and the average market price per share during the year.  Common stock equivalents are not included in the diluted loss per share calculation when their effect is anti-dilutive.
	Since we had no dilutive effect of stock options and warrants for the years ended December 31, 2014 and 2013, our basic weighted average number of common shares outstanding is the same as our diluted weighted average number of common shares outstanding.
Income Taxes	Income Taxes
	We account for income taxes using the asset and liability method.  Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.  The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
Research and Development	Research and Development
	Research and development costs are expensed as incurred.  Total research and development costs were $193,865 and $439 for the years ended December 31, 2014 and 2013, respectively.
Advertising Costs	Advertising Costs
	We expense the cost of advertising and promotional materials when incurred.  We incurred no advertising costs for the years ended December 31, 2014 and 2013.
Stock-based Compensation	Stock-Based Compensation
	Stock-based compensation is measured at the grant date based on the value of the award granted using the Black-Scholes option pricing model, and recognized over the period in which the award vests.  For stock awards no longer expected to vest, any previously recognized stock compensation expense is reversed in the period of termination.  The stock-based compensation expense is included in general and administrative expenses.
Comprehensive Loss	Comprehensive Loss
	Comprehensive loss is the same as net loss for all years presented.
Reclassifications	Reclassifications
	Certain amounts in the prior years have been reclassified to conform to the current year presentation.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements
	In June 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this Update remove the financial statement distinction between development stage entities and other reporting entities from U.S. generally accepted accounting principles (“GAAP”).  In addition, the amendments eliminate the requirements for development stage entities to: (1) present inception-to-date information in the statements of income, cash flows and shareholder equity; (2) label the financial statements as those of a development stage entity; (3) disclose a description of the development stage activities in which the entity is engaged; and (4) disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage.
	For public entities, the amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein.  Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued.  We adopted the provisions of ASU No. 2014-10 during our third fiscal quarter ended September 30, 2014.
	In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 310-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.  The amendments in this Update provide guidance in GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures.  In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures.  The amendments are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter.  Early application is permitted.  We have not determined the impact of the future adoption of the provisions of ASU No. 2014-15 on our financial statements.

2_Summary_of_Significant_Accou2

2. Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Fair Value Measurements, Assets and Liabilities, Recurring Basis (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Fair Value Measurements, Assets and Liabilities, Recurring Basis	We measure certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis are as follows at December 31, 2014 and 2013:
		Total	Level 1	Level 2	Level 3
	December 31, 2014:
	Derivative liability	$     9,476,605	$                 -	$                 -	$     9,476,605
	Convertible notes payable - current	654,199	-	-	654,199
	Convertible notes payable – long-term	61,117	-	-	61,117
	Total liabilities measured at fair value	$   10,191,921	$                 -	$                 -	$   10,191,921
	December 31, 2013:
	Derivative liability	$     2,811,962	$                 -	$                 -	$     2,811,962
	Convertible notes payable	492,904	-	-	492,904
	Total liabilities measured at fair value	$     3,304,866	$                 -	$                 -	$     3,304,866

4_Stock_Options_Warrants_and_R1

4. Stock Options, Warrants and Restricted Stock Awards: Schedule of Stock Options, Activity (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Stock Options, Activity	A summary of the Company’s stock option awards as of December 31, 2014, and changes during the years ended December 31, 2014 and 2013 are as follows:
		Shares	Weighted Average Exercise Price		Weighted Average Remaining Contract Term (Years)	Aggregate Intrinsic Value
	Outstanding at December 31, 2012	1,137,500	$	2.39
	Granted	14,000,000	$	0.006
	Exercised	-	$	-
	Forfeited or expired	-1,037,500	$	2.44
	Outstanding at December 31, 2013	14,100,000	$	0.019	6.72	$   56,000
	Granted	-	$	-
	Exercised	-	$	-
	Forfeited or expired	-	$	-
	Outstanding at December 31, 2014	14,100,000	$	0.019	5.72	$   -
	Exercisable at December 31, 2014	8,500,000	$	0.03	5.72	$  -

6_Convertible_Notes_Payable_Fa

6. Convertible Notes Payable: Fair Value Inputs, Derivative Liability (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Fair Value Inputs, Derivative Liability	The significant assumptions used in the Black Scholes valuation of the derivative liability at December 31, 2014 are as follows:
	Stock price on the valuation date	$0.00
	Conversion price for the debt	$0.0045 - $0.005
	Dividend yield	0	%
	Years to maturity	0.89 - 1.44
	Risk free rate	.14% - .46	%
	Expected volatility	176.60% - 326.86	%

6_Convertible_Notes_Payable_Sc

6. Convertible Notes Payable: Schedule of Derivative Liabilities at Fair Value (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Derivative Liabilities at Fair Value	During the years ended December 31, 2014 and 2013, the Company had the following activity in its derivative liability account:
	Derivative liability at December 31, 2012	$           753,971
	Elimination of liability on conversion	-430,781
	Change in fair value	2,488,772
	Derivative liability at December 31, 2013	2,811,962
	Elimination of liability on conversion	-602,576
	Change in fair value	7,267,219
	Derivative liability at December 31, 2014	$         9,476,605

9_Income_Taxes_Schedule_of_Eff

9. Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the income tax provision (benefit) that would result from applying a combined U.S. federal and state rate of 43% to loss before income taxes with the provision (benefit) for income taxes presented in the financial statements is as follows:
		Years Ended December 31,
		2014	2013
	Income tax benefit at statutory rate	$      (3,313,100)	$      (1,503,900)
	State income taxes, net of federal benefit	-300	-300
	Depreciation	200	800
	Non deductible stock deductions	3,046,900	1,335,100
	Other	-3,000	36,800
	Valuation allowance	269,300	131,500
		$                      -	$                      -

9_Income_Taxes_Schedule_of_Def

9. Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets (liabilities) are comprised of the following:
		December 31,
		2014	2013
	Deferred tax assets:
	Net operating loss carryforward	$3,471,200	$3,204,900
	Research and development credit carryforward	100,100	100,000
	Related party accrued expenses	8,800	4,300
	Accrued compensated absences	600	2,400
	Deferred tax liability:
	Depreciation	-	-200
	Valuation allowance	-3,580,700	-3,311,400
		$-	$-

1_Organization_and_Line_of_Bus1

1. Organization and Line of Business (Details)	12 Months Ended
	Dec. 31, 2014
Details
Entity Incorporation, Date of Incorporation	25-Aug-06

2_Summary_of_Significant_Accou3

2. Summary of Significant Accounting Policies: Property and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Depreciation and amortization	$635	$2,354
Computer Equipment
Property, Plant and Equipment, Useful Life	3 years
Machinery and Equipment
Property, Plant and Equipment, Useful Life	7 years

2_Summary_of_Significant_Accou4

2. Summary of Significant Accounting Policies: Patents and Impairment of Long-lived Assets (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Intangible assets, finite lives, estimated legal life	15 years
Impairment of intangible assets	$1,784	$0

2_Summary_of_Significant_Accou5

2. Summary of Significant Accounting Policies: Fair Value of Financial Instruments: Fair Value Measurements, Assets and Liabilities, Recurring Basis (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Liabilities, Fair Value Disclosure, Recurring	$10,191,921	$3,304,866
Fair Value, Inputs, Level 1
Liabilities, Fair Value Disclosure, Recurring	0	0
Fair Value, Inputs, Level 2
Liabilities, Fair Value Disclosure, Recurring	0	0
Fair Value, Inputs, Level 3
Liabilities, Fair Value Disclosure, Recurring	10,191,921	3,304,866
Derivative Financial Instruments, Liabilities
Liabilities, Fair Value Disclosure, Recurring	9,476,605	2,811,962
Derivative Financial Instruments, Liabilities | Fair Value, Inputs, Level 1
Liabilities, Fair Value Disclosure, Recurring	0	0
Derivative Financial Instruments, Liabilities | Fair Value, Inputs, Level 2
Liabilities, Fair Value Disclosure, Recurring	0	0
Derivative Financial Instruments, Liabilities | Fair Value, Inputs, Level 3
Liabilities, Fair Value Disclosure, Recurring	9,476,605	2,811,962
Convertible notes payable - current
Liabilities, Fair Value Disclosure, Recurring	654,199
Convertible notes payable - current | Fair Value, Inputs, Level 1
Liabilities, Fair Value Disclosure, Recurring	0
Convertible notes payable - current | Fair Value, Inputs, Level 2
Liabilities, Fair Value Disclosure, Recurring	0
Convertible notes payable - current | Fair Value, Inputs, Level 3
Liabilities, Fair Value Disclosure, Recurring	654,199
Convertible notes payable - long-term
Liabilities, Fair Value Disclosure, Recurring	61,117
Convertible notes payable - long-term | Fair Value, Inputs, Level 1
Liabilities, Fair Value Disclosure, Recurring	0
Convertible notes payable - long-term | Fair Value, Inputs, Level 2
Liabilities, Fair Value Disclosure, Recurring	0
Convertible notes payable - long-term | Fair Value, Inputs, Level 3
Liabilities, Fair Value Disclosure, Recurring	61,117
Convertible notes payable
Liabilities, Fair Value Disclosure, Recurring		492,904
Convertible notes payable | Fair Value, Inputs, Level 1
Liabilities, Fair Value Disclosure, Recurring		0
Convertible notes payable | Fair Value, Inputs, Level 2
Liabilities, Fair Value Disclosure, Recurring		0
Convertible notes payable | Fair Value, Inputs, Level 3
Liabilities, Fair Value Disclosure, Recurring		$492,904

2_Summary_of_Significant_Accou6

2. Summary of Significant Accounting Policies: Income (loss) Per Share Calculations (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Potentially Dilutive Shares	0	0

2_Summary_of_Significant_Accou7

2. Summary of Significant Accounting Policies: Research and Development (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Research and development	$193,865	$439

2_Summary_of_Significant_Accou8

2. Summary of Significant Accounting Policies: Advertising Costs (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Advertising Revenue Cost	$0	$0

3_Capital_Stock_Details

3. Capital Stock (Details) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Common Stock, shares authorized	1,000,000,000		1,000,000,000
Common Stock Par Value	$0.00		$0.00
Preferred Stock, shares authorized	20,000,000		20,000,000
Preferred Stock Par Value	$0.00		$0.00
Gain (loss) on settlement of debt	$18,369		($25,195)
Issuance of common stock for accrued services pursuant to restricted stock awards, Value	49,623
Principal
Debt Conversion, Original Debt, Amount	230,385		219,934
Gain (loss) on settlement of debt	18,369		-33,277
Accrued Interest
Debt Conversion, Original Debt, Amount	9,987		5,517
Derivative Liability
Debt Conversion, Original Debt, Amount	602,576
Debt Discount Increase (Decrease)
Debt Conversion, Original Debt, Amount	-47,639
Common Stock
Total Stock Issued During Period	169,051,249
Debt Conversion, Converted Instrument, Shares Issued	163,051,249		59,965,470
Issuance of common stock for accrued services pursuant to restricted stock awards, Shares	6,000,000	[1]
Issuance of common stock for accrued services pursuant to restricted stock awards, Value	$6,000	[1]
Issuance of common stock pursuant to price protection agreement, Shares			592,780
[1]	6,000,000 shares issued at fair value at $.0098 - $0.007 per share

4_Stock_Options_Warrants_and_R2

4. Stock Options, Warrants and Restricted Stock Awards (Details) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2013
Options, Granted	0	14,000,000
Options, Granted, Weighted Average Exercise Price	$0	$0.01
Stock price on the valuation date	$0.00
Warrants, Outstanding	460,000
Warrant, Exercise Price	$0.50
Employee Stock Option
Stock Based Compensation Cost Not yet Recognized	$28,000
Restricted Stock
Stock Based Compensation Cost Not yet Recognized		137,200
Non-Option Equity Instruments, Granted		14,000,000
Equity Instruments Other than Options, Vested in Period	3,000,000
Compensation Expense of Vested Shares	49,623
Consultants
Options, Granted			14,000,000
Options, Granted, Weighted Average Exercise Price			$0.01
Award Vesting Period	25 months
General and Administrative Expense
Allocated Share-based Compensation Expense	$36,825	$101,755

4_Stock_Options_Warrants_and_R3

4. Stock Options, Warrants and Restricted Stock Awards: Schedule of Stock Options, Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Outstanding, Beginning Balance	14,100,000	1,137,500
Outstanding, Weighted Average Exercise Price, Beginning Balance	$0.02	$2.39
Granted	0	14,000,000
Granted, Weighted Average Exercise Price	$0	$0.01
Exercised	0	0
Exercised, Weighted Average Exercise Price	$0	$0
Forfeited or expired	0	-1,037,500
Forfeited or expired, Weighted Average Exercise Price	$0	$2.44
Outstanding, Ending Balance	14,100,000	14,100,000
Outstanding, Weighted Average Exercise Price, Ending Balance	$0.02	$0.02
Outstanding, Weighted Average Remaining Contractual Term	5 years 8 months 19 days	6 years 8 months 19 days
Outstanding, Aggregate Intrinsic Value	$0	$56,000
Exercisable	8,500,000
Exercisable, Weighted Average Exercise Price	$0.03
Exercisable, Weighted Average Remaining Contract Term	5 years 8 months 19 days
Exercisable, Aggregate Intrinsic Value	$0

5_Notes_Payable_Details

5. Notes Payable (Details) (Short Term Promissory Notes, USD $)	Dec. 31, 2013
Debt Instrument, Face Amount	$77,620
Purchased With Cash
Debt Instrument, Face Amount	11,000
Purchased With Accounts Payable
Debt Instrument, Face Amount	40,470
Issued For Services
Debt Instrument, Face Amount	$26,150

6_Convertible_Notes_Payable_De

6. Convertible Notes Payable (Details) (USD $)

12 Months Ended

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 12, 2012

Jul. 08, 2013

Sep. 16, 2013

Jan. 06, 2014

Oct. 24, 2013

Oct. 08, 2012

Feb. 27, 2013

Dec. 10, 2013

Feb. 20, 2014

Jul. 25, 2014

Mar. 14, 2013

29-May-13

Jun. 04, 2013

31-May-13

Sep. 06, 2013

Oct. 08, 2013

Oct. 21, 2013

Nov. 22, 2013

Apr. 18, 2014

20-May-14

Jun. 30, 2014

Jul. 18, 2014

Aug. 06, 2014

Aug. 18, 2014

Sep. 09, 2014

Oct. 08, 2014

Oct. 01, 2014

Nov. 07, 2014

Dec. 09, 2014

Amortization of debt discount and beneficial conversion feature recorded to interest expense

$488,599

$694,795

Proceeds from notes payable

0

11,000

Derivative liability

9,476,605

2,811,962

Gain (loss) on settlement of debt

18,369

-25,195

Principal

Debt Conversion, Original Debt, Amount

230,385

219,934

Gain (loss) on settlement of debt

18,369

-33,277

Accrued Interest

Debt Conversion, Original Debt, Amount

9,987

5,517

Convertible Promissory Note

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Face Amount

75,000

Debt Instrument, Convertible, Terms of Conversion Feature

The notes were convertible into shares of our common stock at a price equal to a variable conversion price of 58% multiplied by a defined market price, representing a discount of 42%. The market price was defined as the average of the lowest three (3) trading prices for our common stock during a ten trading day period ending on the latest complete trading day prior to the conversion date.

Convertible Promissory Note | Principal

Debt Conversion, Original Debt, Amount

75,000

Convertible Promissory Note | Accrued Interest

Debt Conversion, Original Debt, Amount

3,000

Convertible Promissory Note 1a

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Face Amount

42,500

Amortization of debt discount and beneficial conversion feature recorded to interest expense

15,399

Convertible Promissory Note 1a | Principal

Debt Conversion, Original Debt, Amount

42,500

Convertible Promissory Note 1a | Accrued Interest

Debt Conversion, Original Debt, Amount

1,700

Convertible Promissory Note 1b

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Face Amount

32,500

Amortization of debt discount and beneficial conversion feature recorded to interest expense

19,973

Convertible Promissory Note 1b | Principal

Debt Conversion, Original Debt, Amount

32,500

Convertible Promissory Note 1b | Accrued Interest

Debt Conversion, Original Debt, Amount

1,300

Convertible Promissory Note 1c

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Instrument, Face Amount

63,000

Amortization of debt discount and beneficial conversion feature recorded to interest expense

63,000

Convertible promissory notes discount

63,000

Convertible Promissory Note 1c | Principal

Debt Conversion, Original Debt, Amount

16,325

Repayments of Notes Payable

46,675

Convertible Promissory Note 1c | Accrued Interest

Repayments of Notes Payable

18,325

Convertible Promissory Note 1

Debt Instrument, Convertible, Terms of Conversion Feature

The notes are convertible into shares of our common stock at a price equal to a variable conversion price of $58% multiplied by a defined market price, representing a discount of 42%. The market price is defined as the average of the lowest three trading prices for our common stock during a ten trading day period ending on the latest complete trading day prior to the conversion date.

Convertible Promissory Note 2

Debt Instrument, Face Amount

327,500

Convertible Promissory Note 3

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into shares of our common stock at a conversion price equal to (a) the lesser of $0.54 per share or (b) 50% of the lowest trade price recorded on any trade date after the effective date, or (c) the lowest effective price per share granted to any person after the effective date.

Amortization of debt discount and beneficial conversion feature recorded to interest expense

312,740

Convertible promissory notes discount

327,500

Amount transferred to another investor

62,000

Convertible Promissory Note 3 | Principal

Debt Conversion, Original Debt, Amount

36,057

Convertible Promissory Note 3 | Accrued Interest

Debt Conversion, Original Debt, Amount

886

Convertible Promissory Note 4

Debt Instrument, Interest Rate, Stated Percentage

299212.00%

Debt Instrument, Face Amount

233,012

282,462

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into shares of our common stock at a conversion price equal to (a) the lesser of $0.006 per share or (b) 50% of the lowest trade price recorded on any trade date after the effective date, or (c) the lowest effective price per share granted to any person after the effective date

Debt Instrument, Maturity Date

30-Jun-15

Convertible Promissory Note 4 | Principal

Debt Instrument, Face Amount

291,443

Debt Conversion, Original Debt, Amount

49,450

16,750

Convertible Promissory Note 4 | Accrued Interest

Debt Instrument, Face Amount

7,769

Debt Conversion, Original Debt, Amount

6,986

1,631

Convertible Promissory Note 5

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Debt Instrument, Face Amount

244,452

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into shares of our common stock at a conversion price equal to the lesser of $0.20 per share or the closing price per share of common stock recorded on the trading day immediately preceding the date of conversion

Amortization of debt discount and beneficial conversion feature recorded to interest expense

120,958

118,993

Convertible promissory notes discount

237,742

Debt Instrument, Maturity Date

31-Dec-15

Convertible Promissory Note 5 | Board of Directors Chairman

Debt Instrument, Face Amount

185,852

Debt Instrument, Maturity Date

31-Dec-15

Convertible Promissory Note 5 | Principal | Board of Directors Chairman

Debt Instrument, Face Amount

185,852

185,852

Convertible Promissory Note 5 | Accrued Interest | Board of Directors Chairman

Debt Instrument, Face Amount

18,585

9,293

Convertible Promissory Note 6

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Face Amount

100,000

Debt Instrument, Convertible, Terms of Conversion Feature

The notes are convertible into shares of our common stock at a price equal to a variable conversion price of the lesser of $0.09 per share or fifty percent (50%) of the lowest trade price recorded after the effective date

Amortization of debt discount and beneficial conversion feature recorded to interest expense

8,849

31,151

Convertible promissory notes discount

40,000

Debt Instrument, Maturity Date

30-Jun-15

Proceeds from notes payable

40,000

Convertible Promissory Note 7

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Face Amount

335,000

Debt Instrument, Convertible, Terms of Conversion Feature

The notes are convertible into shares of our common stock at a price equal to the lesser of $0.72 or 70% of the lowest trading price in the 25 trading days prior to the conversion.

Debt Conversion, Original Debt, Amount

80,844

Amortization of debt discount and beneficial conversion feature recorded to interest expense

43,283

Amount transferred to another investor

2,906

Proceeds from notes payable

75,000

Original issue discount

35,000

Long-term Debt, Gross

83,750

Debt Instrument, Interest Rate Terms

If the notes issued under the $335,000 SPA are repaid before 90 days, the interest rate will be zero percent (0%), otherwise a one-time interest rate of five percent (5%) will be applied to the principal sums outstanding

Convertible Promissory Note 7 | Principal

Amount transferred to another investor

2,906

Long-term Debt, Gross

75,000

Convertible Promissory Note 7 | Accrued Interest

Amount transferred to another investor

4,188

Convertible Promissory Note 7 | Original Issue Discount

Convertible promissory notes discount

8,750

Original issue discount percent

10.00%

Convertible Promissory Note 7 | Unamortized Original Issue Discount

Long-term Debt, Gross

8,750

Convertible Promissory Note 7 | Conversion Feature

Convertible promissory notes discount

54,843

Convertible Promissory Note 8

Debt Instrument, Face Amount

25,000

Debt Conversion, Original Debt, Amount

11,284

Amortization of debt discount and beneficial conversion feature recorded to interest expense

2,137

23,266

Convertible promissory notes discount

25,403

Amount transferred to another investor

7,239

Original issue discount

2,917

Long-term Debt, Gross

27,917

Convertible Promissory Note 8 | Principal

Debt Conversion, Original Debt, Amount

25,122

Convertible Promissory Note 8 | Accrued Interest

Debt Conversion, Original Debt, Amount

1,250

Convertible Promissory Note 9

Debt Conversion, Original Debt, Amount

29,313

Amortization of debt discount and beneficial conversion feature recorded to interest expense

27,627

Convertible promissory notes discount

29,313

Proceeds from notes payable

25,000

Original issue discount

4,313

Long-term Debt, Gross

29,313

Convertible Promissory Note 10

Debt Conversion, Original Debt, Amount

35,175

Amortization of debt discount and beneficial conversion feature recorded to interest expense

35,175

Convertible promissory notes discount

35,175

Proceeds from notes payable

30,000

Original issue discount

5,175

Long-term Debt, Gross

35,175

Convertible Promissory Note 11

Amortization of debt discount and beneficial conversion feature recorded to interest expense

27,917

Proceeds from notes payable

25,000

Original issue discount

2,917

Long-term Debt, Gross

27,917

Repayments of Debt

27,917

Convertible Promissory Note 12

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Debt Instrument, Face Amount

29,500

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into shares of our common stock at a conversion price equal to the lesser of $0.15 per share or the closing price per share of common stock recorded on the trading day immediately preceding the date of conversion

Debt Instrument, Maturity Date

14-Mar-15

Convertible Promissory Note 13

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Face Amount

97,000

Debt Instrument, Convertible, Terms of Conversion Feature

The note is convertible into shares of our common stock at a price equal to a conversion price of the lesser of $0.028 per share or fifty percent (50%) of the lowest trade price recorded after the effective date.

Amortization of debt discount and beneficial conversion feature recorded to interest expense

97,000

Convertible promissory notes discount

97,000

Debt Instrument, Maturity Date

30-Jun-15

Convertible Promissory Note 14 | Director

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Debt Instrument, Face Amount

25,000

25,000

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into shares of common stock of the Company at a conversion price equal to the lesser of $0.035 per share or the closing price per share of common stock recorded on the trading day immediately preceding the date of conversion

Debt Instrument, Maturity Date

4-Jun-16

Convertible Promissory Note 15 | Chief Executive Officer

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Debt Instrument, Face Amount

15,000

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into shares of our common stock at a conversion price equal to the lesser of $0.04 per share or the closing price per share of common stock recorded on the trading day immediately preceding the date of conversion

Convertible Promissory Note 16

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Face Amount

5,000

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into shares of our common stock at a price equal to a conversion price of the lesser of $0.0042 per share or fifty percent (50%) of the lowest trade price recorded after the effective date

Amortization of debt discount and beneficial conversion feature recorded to interest expense

1,459

1,077

Convertible promissory notes discount

2,536

Debt Instrument, Maturity Date

30-Jun-15

Convertible Promissory Note 17

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Face Amount

250,000

Debt Instrument, Convertible, Terms of Conversion Feature

convertible into shares of common stock of the Company at a price equal to the lesser of $0.006 or 50% of the lowest trade price subsequent to the effective date of the note and prior to the conversion

Debt Instrument, Maturity Date

30-Jun-15

Convertible Promissory Note 17 | Advance 1

Debt Instrument, Face Amount

11,000

Amortization of debt discount and beneficial conversion feature recorded to interest expense

5,863

5,137

Convertible promissory notes discount

11,000

Convertible Promissory Note 17 | Advance 2

Debt Instrument, Face Amount

22,000

Amortization of debt discount and beneficial conversion feature recorded to interest expense

13,418

8,582

Convertible promissory notes discount

22,000

Convertible Promissory Note 17 | Advance 3

Debt Instrument, Face Amount

25,000

Amortization of debt discount and beneficial conversion feature recorded to interest expense

19,613

5,387

Convertible promissory notes discount

25,000

Convertible Promissory Note 18

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Face Amount

500,000

Debt Instrument, Convertible, Terms of Conversion Feature

The notes are convertible into shares of our common stock at a price per share equal to the lesser of: $0.003; 50% of the lowest trade price subsequent to the effective date of the note and prior to the conversion; or the lowest effective price per share granted to any person or entity to acquire common stock subsequent to the effective date of the note

Convertible Promissory Note 18 | Advance 1

Debt Instrument, Face Amount

60,000

Amortization of debt discount and beneficial conversion feature recorded to interest expense

28,139

Convertible promissory notes discount

31,861

60,000

Convertible Promissory Note 18 | Advance 2

Debt Instrument, Face Amount

45,000

Amortization of debt discount and beneficial conversion feature recorded to interest expense

18,443

Convertible promissory notes discount

26,557

45,000

Convertible Promissory Note 18 | Advance 3

Debt Instrument, Face Amount

200,000

Amortization of debt discount and beneficial conversion feature recorded to interest expense

67,153

Convertible promissory notes discount

132,847

200,000

Convertible Promissory Note 18 | Advance 4

Debt Instrument, Face Amount

25,000

Amortization of debt discount and beneficial conversion feature recorded to interest expense

7,559

Convertible promissory notes discount

17,441

25,000

Convertible Promissory Note 18 | Advance 5

Debt Instrument, Face Amount

65,000

Amortization of debt discount and beneficial conversion feature recorded to interest expense

17,404

Convertible promissory notes discount

47,596

65,000

Convertible Promissory Note 18 | Advance 6

Debt Instrument, Face Amount

25,000

Amortization of debt discount and beneficial conversion feature recorded to interest expense

6,148

Convertible promissory notes discount

18,852

25,000

Convertible Promissory Note 18 | Advance 7

Debt Instrument, Face Amount

56,000

Amortization of debt discount and beneficial conversion feature recorded to interest expense

11,569

Convertible promissory notes discount

44,431

56,000

Convertible Promissory Note 18 | Advance 8

Debt Instrument, Face Amount

24,000

Amortization of debt discount and beneficial conversion feature recorded to interest expense

3,679

Convertible promissory notes discount

20,321

24,000

Convertible Promissory Note 19

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Debt Instrument, Face Amount

500,000

Debt Instrument, Convertible, Terms of Conversion Feature

The notes are convertible into shares of our common stock at a price per share equal to the lesser of: $0.003; 50% of the lowest trade price subsequent to the effective date of the note and prior to the conversion; or the lowest effective price per share granted to any person or entity to acquire common stock subsequent to the effective date of the note

Convertible Promissory Note 19 | Advance 1

Debt Instrument, Face Amount

65,000

Amortization of debt discount and beneficial conversion feature recorded to interest expense

10,794

Convertible promissory notes discount

54,206

65,000

Convertible Promissory Note 19 | Advance 2

Debt Instrument, Face Amount

30,000

Amortization of debt discount and beneficial conversion feature recorded to interest expense

2,962

Convertible promissory notes discount

27,038

30,000

Convertible Promissory Note 19 | Advance 3

Debt Instrument, Face Amount

25,000

Amortization of debt discount and beneficial conversion feature recorded to interest expense

1,004

Convertible promissory notes discount

$23,996

$25,000

6_Convertible_Notes_Payable_Fa1

6. Convertible Notes Payable: Fair Value Inputs, Derivative Liability (Details) (USD $)	12 Months Ended
	Dec. 31, 2014
Stock price on the valuation date	$0.00
Dividend yield	0.00%
Minimum
Conversion price for the debt	$0.00
Years to maturity	10 months 20 days
Risk free rate	0.14%
Expected volatility	176.60%
Maximum
Conversion price for the debt	$0.01
Years to maturity	1 year 5 months 8 days
Risk free rate	0.46%
Expected volatility	326.86%

6_Convertible_Notes_Payable_Sc1

6. Convertible Notes Payable: Schedule of Derivative Liabilities at Fair Value (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Derivative liability, starting balance	$2,811,962	$753,971
Elimination of liability on conversion	-602,576	-430,781
Change in fair value	7,267,219	2,488,772
Derivative liability, ending balance	$9,476,605	$2,811,962

7_Research_Agreement_Details

7. Research Agreement (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Sponsored Research Agreement Total Cost	$387,730
Sponsored Research Agreement Payment Schedule Description	$200,000 on or before July 1, 2014 $62,577 on October 1, 2014 $62,577 On January 1, 2015 $62,576 on April 1, 2015
Prepaid expenses	70,593	3,758
Research and Development Expense
Prepaid expenses	193,865
Sponsored Research Agreement
Prepaid expenses	$68,712

8_Supplemental_Statement_of_Ca1

8. Supplemental Statement of Cash Flows Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2014		Dec. 31, 2013
Income Taxes Paid	$0		$0
Interest Paid	18,983		4,333
Issuance of common stock for conversion of notes payable, Value	776,940		600,290
Increase Decrease in Debt Discount for the Period	-47,639		-55,942
Increase (Decrease) in Derivative Liabilities	-602,576		-430,781
Issuance of common stock for accrued services pursuant to restricted stock awards, Value	49,623
Contribution of accrued interest to capital			7,175
Increase (Decrease) in Interest Payable, Net			-11,955
Issuance Of New Notes During Period
Increase Decrease in Debt Discount for the Period			-8,986
Increase (Decrease) in Derivative Liabilities	738,000		6,585
Increase or (decrease) during the reporting period in additional paid in capital in relation to beneficial conversion features.			138,951
Increase (decrease) during the reporting period of additional paid in capital			-15,571
Contribution Of Related Party Accrued Interest To Capital
Contribution of accrued interest to capital			7,175
Increase (Decrease) in Interest Payable, Net			-7,175
Note Contributed To Capital
Increase (decrease) during the reporting period of additional paid in capital			15,000
Debt Instrument, Increase (Decrease), Net	15,000		15,000
Principal
Debt Conversion, Original Debt, Amount	230,385		219,934
Accrued Interest
Debt Conversion, Original Debt, Amount	9,987		5,517
Exchanged For Convertible Notes Payable
Amount transferred to another investor			82,620
Exchange For Accounts Payable 1
Notes Issued			29,500
Exchange For Accounts Payable 2
Notes Issued			40,470
Common Stock
Issuance of common stock for conversion of notes payable, Shares	163,051,249	[1]	59,965,470	[2]
Issuance of common stock for conversion of notes payable, Value	163,051	[1]	59,965	[2]
Issuance of common stock for accrued services pursuant to restricted stock awards, Shares	6,000,000	[3]
Issuance of common stock for accrued services pursuant to restricted stock awards, Value	6,000	[3]
Issuance of common stock pursuant to price protection agreement, Shares			592,780
Issuance of common stock pursuant to price protection agreement, Value			593
Additional Paid-in Capital
Issuance of common stock for conversion of notes payable, Value	613,889		540,325
Issuance of common stock for accrued services pursuant to restricted stock awards, Value	43,623
Issuance of common stock pursuant to price protection agreement, Value			-593
Contribution of accrued interest to capital			$7,175
[1]	44,783,036 shares issued at fair value at $0.0017 - $0.0041 per share; 54,697,929 shares issued at fair value at $0.00294 per share; 63,570,284 shares issued at fair value at $0.00045 per share
[2]	12,020,445 shares issued at fair value at $0.0035 - $0.013 per share; 6,939,995 shares issued at fair value at $0.0035 - $0.012 per share; 23,090,000 shares issued at fair value at $0.0069 - $0.012 per share; 17,915,030 shares issued at fair value at $0.006 - $0.012 per share
[3]	6,000,000 shares issued at fair value at $.0098 - $0.007 per share

9_Income_Taxes_Schedule_of_Eff1

9. Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Details
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	43.00%
Income tax benefit at statutory rate	($3,313,100)	($1,503,900)
State income taxes, net of federal benefit	-300	-300
Depreciation	200	800
Nondeductible stock deductions	3,046,900	1,335,100
Other	-3,000	36,800
Valuation allowance	269,300	131,500
Income Tax Expense (Benefit), Total

9_Income_Taxes_Schedule_of_Def1

9. Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carryforward	$3,471,200	$3,204,900
Research and development credit carryforward	100,100	100,000
Related party accrued expenses	8,800	4,300
Accrued compensated absences	600	2,400
Deferred tax liability:
Depreciation	0	-200
Valuation allowance	-3,580,700	-3,311,400
Deferred Tax Assets, Net, Total	$0	$0

9_Income_Taxes_Details

9. Income Taxes (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Details
Operating Loss Carryforwards	$8,072,000
Unrecognized Tax Benefits	$0	$0

10_Related_Party_Transactions_

10. Related Party Transactions (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2014	Dec. 31, 2012	Jun. 04, 2013	31-May-13
Accrued interest, notes payable	$64,340	141,434
Contribution of accrued interest to capital	7,175
Convertible Promissory Note 5
Debt Instrument, Face Amount			244,452
Debt Instrument, Maturity Date		31-Dec-15
Convertible Promissory Note 5 | Board of Directors Chairman
Debt Instrument, Face Amount			185,852
Debt Instrument, Maturity Date		31-Dec-15
Convertible Promissory Note 5 | Board of Directors Chairman | Principal
Debt Instrument, Face Amount	185,852	185,852
Convertible Promissory Note 5 | Board of Directors Chairman | Accrued Interest
Debt Instrument, Face Amount	9,293	18,585
Convertible Promissory Note 14 | Director
Debt Instrument, Face Amount		25,000		25,000
Debt Instrument, Maturity Date		4-Jun-16
Accrued interest, notes payable	719	1,969
Convertible Promissory Note 15 | Chief Executive Officer
Debt Instrument, Face Amount					15,000
Note Contributed To Capital
Increase (decrease) during the reporting period of additional paid in capital	15,000
Debt Instrument, Increase (Decrease), Net	15,000	15,000
Contribution Of Related Party Accrued Interest To Capital
Contribution of accrued interest to capital	$7,175

11_Operating_Lease_Details

11. Operating Lease (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Sep. 30, 2013
Details
Lease Expiration Date	30-Sep-17
Operating Lease Monthly Payment Amount	$2,971		$2,884
Operating Leases, Rent Expense	$58,306	$53,045

12_Consulting_Agreements_Detai

12. Consulting Agreements (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Mitr Consulting Corporation
Consulting Fee, per month	$5,000
Chief Executive Officer
Consulting Fee, per month		$5,000

12_Subsequent_Events_Details

12. Subsequent Events (Details) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Feb. 28, 2015	Jan. 31, 2015
Entity Incorporation, Date of Incorporation	25-Aug-06
Research and development	$193,865	$439
Proceeds from convertible notes payable	738,000	242,380
Principal
Debt Conversion, Original Debt, Amount	230,385	219,934
Accrued Interest
Debt Conversion, Original Debt, Amount	9,987	5,517
Common Stock
Debt Conversion, Converted Instrument, Shares Issued	163,051,249	59,965,470
Subsequent Event
Proceeds from convertible notes payable			30,000	92,000
Subsequent Event | Principal
Debt Conversion, Original Debt, Amount	9,200
Subsequent Event | Accrued Interest
Debt Conversion, Original Debt, Amount	1,956
Subsequent Event | Common Stock
Debt Conversion, Converted Instrument, Shares Issued	24,790,746
Subsequent Event | Sponsored Research Agreement
Research and development				$62,577
Subsequent Event | Transphene, Inc.
Entity Incorporation, Date of Incorporation	5-Jan-15
Noncontrolling Interest, Ownership Percentage by Parent	50.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	50.00%